Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses how novel treatment options have revolutionized treatment for patients with non-small cell lung cancer, a disease that used to be considered “beyond surgery.”

Novel therapies, new characterizations of tumors, and a more personalized approach to treating these tumors will be discussed at the upcoming 

New Frontiers In The Management of Solid and Liquid Tumors

 conference at John Theurer Cancer Center at Hackensack University Medical Center, November 3-4, 2011.

Videos

Dr. Andre Goy from John Theurer Cancer Center on Integrating Novel Therapies Into the JTCC Conference

Dr. Goy on Novel Therapies at the JTCC Conference

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, recognizes that this is a very exciting time for the field of oncology. There are multiple novel therapies, predictors, and biomarkers currently being investigated. It is a daunting task for the busy oncology specialist to keep up on all this new information.

The upcoming New Frontiers in the Management of Solid and Liquid Tumors at John Theurer Cancer Center at Hackensack University Medical Center, November 3-4, 2011, will broadly explain the recent advances in these multiple fields. This information will help the clinician manage patients by facilitating the application of this knowledge into practice.

Dr. Andre Goy from John Theurer Cancer Center on the Upcoming Conference at John Theurer Cancer Center

Andre Goy, MD, John Theurer Cancer Center

Articles

Dr. Goy on Novel Therapies at the JTCC Conference

Dr. Goy on the Upcoming Conference at the JTCC